Your cart is empty
Browse CatalogJune 7, 2025
The enzymatic degradation of peptides by proteases represents the primary clearance mechanism limiting the in vivo half-life and therapeutic utility of peptide-based drugs and research tools. The human body expresses hundreds of distinct proteases belonging to five major catalytic classes: serine proteases, cysteine proteases, aspartate proteases, metalloproteases, and threonine proteases. Each class employs a distinct catalytic mechanism for hydrolysis of the peptide bond, and individual proteases within each class exhibit varying degrees of sequence specificity ranging from the broad-spectrum activity of proteinase K to the exquisite selectivity of thrombin for its Arg-Gly cleavage site. Understanding the specific proteases responsible for degradation of a given peptide therapeutic is essential for rational design of stabilization strategies.
Peptide degradation begins immediately upon administration, with the specific enzymes encountered depending on the route of administration. Orally administered peptides face the gastrointestinal protease gauntlet including pepsin in the stomach, trypsin and chymotrypsin in the small intestine, and brush border membrane peptidases on enterocyte surfaces. Parenterally administered peptides are subject to plasma proteases including dipeptidyl peptidase IV, angiotensin-converting enzyme, and neutral endopeptidase, as well as tissue-associated enzymes at the injection site. The susceptibility of specific peptide bonds to proteolytic cleavage is governed by the amino acid sequence flanking the scissile bond, local backbone flexibility, and steric accessibility. Computational prediction tools trained on protease specificity databases can now identify likely degradation sites in silico, guiding the strategic placement of stabilizing modifications.
A comprehensive arsenal of chemical modification strategies has been developed to protect peptides from enzymatic degradation while preserving their biological activity. D-amino acid substitution at identified cleavage sites is among the most effective approaches, as most endogenous proteases exhibit strict stereospecificity for L-configured substrates. N-methylation of backbone amides similarly confers protease resistance by sterically occluding the active site of the degrading enzyme. C-terminal amidation and N-terminal acetylation protect against exopeptidase activity, while backbone modifications including reduced amide bonds, ester isosteres, and beta-amino acid insertions create local perturbations in the peptide bond geometry that prevent productive binding to protease active sites. The art of peptide stabilization lies in identifying the minimum set of modifications that confers adequate metabolic stability without compromising receptor binding affinity or selectivity.